Status:
NOT_YET_RECRUITING
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Lead Sponsor:
Jason Ahee, M.D.
Conditions:
Endophthalmitis
Eligibility:
All Genders
40+ years
Phase:
PHASE2
PHASE3
Brief Summary
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
Detailed Description
Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically signif...
Eligibility Criteria
Inclusion
- visually significant cataracts
Exclusion
- allergy to fluoroquinolones, cobalamin (B12)
Key Trial Info
Start Date :
June 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2031
Estimated Enrollment :
60000 Patients enrolled
Trial Details
Trial ID
NCT03244072
Start Date
June 1 2026
End Date
October 1 2031
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zion Eye Institute
St. George, Utah, United States, 84790